

## ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Charpentier KP, Von Moltke LL, Poku JW, Haramatz JS, Shader RI, Greenblatt DJ. Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. *Biopharmaceutics and Drug Disposition* 1997; 18(2):139-149.
2. Charpentier KP, Welch H. Pseudoaneurysm of the superior mesenteric artery secondary to ergot therapy: a case report. *Vascular Surgery* 1999; 33(3):335-39.
3. Black PC, Charpentier, KP, Bakthavatsalam R, Marsh C, Porter J. Hand-Assisted, laparoscopic right donor nephrectomy in a patient with situs inversus. *Transplantation*. 2003 Nov 27;76(10):1530.
4. Martay K, Dembo G, Vater Y, Charpentier KP, Levy A, Bakthavatsalam, R Freund PR. Unexpected surgical difficulties leading to hemorrhage and gas embolus during laparoscopic donor nephrectomy: a case report. *Can J Anaesth*. 2003 Nov;50(9):891-4.
5. Charpentier KP, Brentnall TA, Bronner MP, Byrd D, Marsh C. A new indication for pancreas transplantation: high-grade pancreatic dysplasia. *Clin Transplant*. 2004 Feb;18(1):105-7.
6. Friedrich J, Charpentier KP, Marsh CL, Bakthavatsalam R, Levy A, Kuhr CS. Outcomes with the selective use of enteric exocrine drainage in pancreas transplantation. *Transplant Proc*. 2004;36:3101-04.
7. Ojo P, Ranga KV, Brown M, Hull D, Charpentier KP. Transplantation of a unilateral fused kidney with inferior ectopia: revascularization utilizing donor aorta and vena cava. *Conn Med* 2008;72(10):585-8.
8. Charpentier KP, Mavanur A. Removing patients from the liver transplant waitlist: a survey of United States liver transplant programs. *Liver Transpl* 2008;14:303-8.
9. Charpentier KP, Cheah YL, Machan JT, Miner T, Morrissey P, Monaco A. Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area. *HPB* 2008;10: 412-15.
10. Yango A, Gohh R, Fischer S, Morrissey P, Charpentier K, Monaco A. The Utility of 6 Month Protocol Renal Biopsy under Modern Immunosuppression. *Clin Nephrol* 2008;70(6):490-5.
11. Charpentier KP, Wolf F, Resnick M, Noble L, Winn B, Dupuy D. Irreversible electroporation of the pancreas in swine: a pilot study. *HPB* 2010;12(5):348-51.

12. Thomay A, Charpentier KP. Optimizing resection for responding hepatic metastases after neoadjuvant chemotherapy. *J Surg Oncol* 2010;102:1002-8.
13. Jackson KL, Charpentier KP. Quantitative banding for steal syndrome secondary to arteriovenous fistulae. *Ann R Coll Surg Engl* 2010; 92:534.
14. Safran H, Miner T, Bahary N, Whiting S, Lopez C, Sun W, Charpentier K, Shipley J, Anderson E, McNulty B, Schumacher A, Clark A, Vakharia J, Kennedy T. Lapatinib and Gemcitabine for metastatic pancreatic cancer: A phase II study. *Am J Clin Oncol* 2011;34(1):50-52.
15. Charpentier KP, Wolf F, Resnick M, Noble L, Winn B, Dupuy D. Irreversible electroporation of the liver and liver hilum in swine. *HPB* 2011;13:168-173.
16. Miner TJ, Cohen J, Charpentier KP, McPhillips J, Marvell L, Cioffi W. The Palliative Triangle: Better Patient Selection Improves Outcomes Following Palliative Operations. *Arch Surg* 2011; 146(5):517-23.
17. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands JR. Tumor progression-related transmembrane protein aspartate b-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. *J Hepatol* 2012;56(5):1129-35.
18. Charpentier, KP. Irreversible electroporation for the ablation of liver tumors: Are we there yet? *Arch Surg*. Accepted for publication 5/2012.
19. Safran H, Charpentier KP, Kaubisch A, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Mantripragada K, Berz D, Luppe D, Martel D, Rosati K, Santiago A and Isdale D. Lenalidomide for Second-Line Treatment of Advanced Hepatocellular Cancer: A Brown University Oncology Group Phase II Study. *J Clin Oncol* accepted for publication 11/2012.
20. Ratanaprasatporn L, Dupuy D, Resnick M, Lu S, Charpentier KP. Intra-Operative Microwave Ablation of Liver Malignancies with Tumor Permittivity Feedback Control: A Prospective Ablate and Resect Study. *HPB* accepted 1/2013.
21. Sibulesky L, Charpentier K, Gohh RY, Morrissey PE. Kidney Transplantation from Donors with Severe Disseminated Intravascular Coagulation. *International Scholarly Research Network (ISRN) ó Transplantation*, Accepted 1/2013.

## **BOOK CHAPTERS**

1. Charpentier KP. Multi-modality approach to the management of hepatocellular carcinoma. In: Sunitha M, editor. Current Research in Hepatology. Research Media; 2008. p.83-98.

## **OTHER PUBLICATIONS**

1. Charpentier KP. The goal of trauma and critical care teams includes restitution of the acutely injured patient. J Trauma. 2005 Sep;59(3):785.
2. Charpentier KP, Levy A, Davis CL, Robertson RP, Reems JA, Marsh CL. Acalculous cholecystitis complicating simultaneous kidney and islet transplantation. Surg Rounds 2004;27:335-7.

## **PUBLICATIONS SUBMITTED OR IN PREPARATION**

- 1 Richman K, Yango A, Garber C, Morrissey P, Charpentier K, Fischer S, Nelson B; Monaco A, Gohh R. Physical Function Before and After Renal Transplantation. Clinical Transplantation, submitted 2/2011.
- 2 Jackson KL, Grand DJ, Resnick MB, Charpentier KP. Varying Clinical and radiographic presentation of duodenal gastrointestinal stromal tumors. HPB, submitted.
- 3 Alexander E, Wolf FJ, Machan JT, Charpentier KP, Iannuccilli J, Hass RA, Dupuy DE. Microwave ablation of focal hepatic malignancies regardless of size: short-term safety and efficacy. Manuscript in preparation.
- 4 Okhah Z, Morrissey P, Harrington D, Cioffi W, Charpentier KP. Performance assessment of surgical residents in a vascular anastomosis laboratory. Journal of the American College of Surgeons, submitted 12/2011.
- 5 Mangray S, Charpentier KP. Hepatic Capillaritis Masquerading as Metastatic Colorectal Cancer, manuscript in preparation.

## **ABSTRACTS**

1. Bonadies J, Benbrahim A, Charpentier KP, Reinhold RB. Ranson's criteria in non-pancreatic critical illness. The Society for Surgery of the Alimentary Tract. May 1997.
2. Charpentier KP, Ciardiello KA. The use of CT scan and small bowel series in the management of small bowel obstruction. The Connecticut State Chapter of the American College of Surgeons. December 1998.

3. Charpentier KP, Pae T, Reinhold R. Pancreatitis in the elderly. The Connecticut State Chapter of the American College of Surgeons. November 1999.
4. Brown MG, Hull D, Bartus SA, Schweizer RT, Lipkowitz G, Madden R, Charpentier KP. Controlled nonheartbeating donors are an effective and underutilized source of liver allografts. American Society of Transplantation, 2000.
5. Charpentier KP, Pae T, Reinhold RB. Optimal treatment of gallstone pancreatitis in patients over 80. American Hepato-Pancreato-Biliary Association. Annual Congress Meeting. Feb 2001.
6. Charpentier KP, Brentnall T, Bronner M, Byrd D and Marsh C. High-grade pancreatic dysplasia, a new and rare indication for pancreas transplant. American Society of Transplant Surgeons Winter Symposium, "Tumors in Transplantation." January 2003.
7. Charpentier KP, Isom C, Kuhr CS, Davis C, Levy A, Bathvatsalam R, Marsh CL. Pancreas Transplantation in the absence of steroid based immunosuppression. American College of Surgeons/Washington State Chapter Annual Meeting, Bend OR. June 2003.
8. Niranjan S, Balarezo F, Alleman K, Brown M, Charpentier K, Lally A, Hull D, Ranga KV. Chronic allograft damage index (CADI) scoring at conversion from calcineuron inhibitors (CI) to sirolimus predicts renal outcome in kidney transplant recipients. American Transplant Congress, Boston, MA. May 2004.
9. Niranjan S, Alleman K, Brown M, Charpentier K, Lally A, Hull D, Cooper B, Lawlor M, Ranga KV. Cytomegalovirus immune globulin (Ig) alone does not prevent seroconversion in CMV mismatched kidney transplant recipients receiving non-lytic induction therapy. XX International Congress of The Transplantation Society, Vienna. September 2004.
10. Ojo P, Hull D, Brown M, Charpentier KP. Successful transplantation of a solitary fused kidney using the donor aorta and vena cava for revascularization: How we did it. The Connecticut State Chapter of the American College of Surgeons. November 2004.
11. Haider L, Benson S, White A, Brown MG, Lally AL, Hull D, Charpentier KP, Ranga KV. Successful Living Kidney Donation From A Donor With Gitelman Syndrome. National Kidney Foundation Meeting, Washington D.C. May 2005.
12. Fontanilla JM, Haider L, Meyer A, Rocca G, Czerniak E, Brown MG, Lally AL, Hull D, Charpentier KP, Ranga KV. Valacyclovir Alone Is Not Effective Antiviral Prophylaxis Against Cytomegalovirus (CMV) Infection In CMV

Positive Recipients Of CMV Negative Kidneys In Renal Transplantation.  
National Kidney Foundation Meeting, Washington D.C. May 2005.

13. Hull D, Polio J, Bee ER, Lally AL, Charpentier KP, Isreal J, Hoffman M, Ranga KV, Palmeri DL, Brown MG. Retrospective study of liver transplant MELD scores and outcomes: A single center experience. American Transplant Congress, Seattle, WA. May 2005.
14. Greene T and Charpentier KP. Cadaver donor hyperglycemia as a risk factor and predictor of delayed graft function in kidney transplant. New England/Northeastern Section of the American Urologic Association, Bermuda. November 2005.
15. Mavanur A, Charpentier KP, Brown M, Hull D, Lally A, Israel J, Hoffman M and Polio J. Removing patients from the liver transplant waitlist: A survey of United States liver transplant programs. Joint International Congress of the International Liver Transplant Society (ILTS), European Liver and Intestinal Transplant Association (ELITA), and the Liver Intensive Care Group of Europe (LICAGE), Milan, Italy. May 2006.
16. Fernandez H, Madadi S, Palmieri D, Charpentier K, Lally A, Brown M, Hull D, Hoffman M, Israel J, Polio J and Ranga KV. Cytomegalovirus (CMV) immunoglobulin does not confer any additional protection along with newer antiviral prophylaxis for prevention of CMV infection in high risk liver transplant recipients. Joint International Congress of the International Liver Transplant Society (ILTS), European Liver and Intestinal Transplant Association (ELITA), and the Liver Intensive Care Group of Europe (LICAGE), Milan, Italy. May 2006.
17. Yango A, Gohh R, Fischer S, Morrissey P, Charpentier K, Monaco A. Utility of protocol biopsy in stable renal transplant recipients under Tacrolimus-based immune suppression. Transplant Summit 2007, Chicago, IL. September 2007.
18. Rathore R, Soares G, Bass J, McNulty B, Charpentier K, Iannitti D, Wanebo H, Safran H. Hepatic arterial infusion (HAI) oxaliplatin in advanced hepatocellular cancer (HCC): A Phase I Brown University Oncology Group study. Gastrointestinal Cancers Symposium 2008. Orlando, FL, January 2008.
19. Charpentier KP, Cheah YL, Machan JT, Miner T, Morrissey P, Monaco A. Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area. American Hepato-Pancreatico-Biliary Association Annual Meeting. Ft. Lauderdale, FL, March 2008.

20. Tan TW, Morrissey PE, Gohh RY, Yango AF, Charpentier KP, Monaco AP. One year outcomes following live donor nephrectomy in high-risk donors. American Transplant Congress. Toronto, Canada June 2008.
21. Garber CE, Nelson B, Yango AF, Morrissey PE, Charpentier KP, Gohh RY. Physical function in patients awaiting renal transplantation. American Transplant Congress. Toronto, Canada June 2008.
22. Go S, Gohh R, Monaco A, Charpentier K, Morrissey P, Machan J, Yango A. Post transplant anemia at six months increases the risk of graft loss and mortality among kidney transplant patients. American Transplant Congress. Toronto, Canada June 2008.
23. Del Signore A, Morrissey P, Fischer S, Gohh R, Machan J, Monaco A, Yango A, Young C, Charpentier KP. Early Graft Function in Pre-emptive Versus Previously Dialyzed Live Donor Kidney Transplant Recipients. New England Surgical Society, Boston, MA September 2008.
24. Chiu R, Machan J, Gohh R, Fischer S, Charpentier K, Morrissey P, Monaco A, Yango A. Death after graft failure: A single center experience. American Transplant Congress, Boston, MA, June 2009.
25. Safran H, Miner T, Bahary N, Whiting S, Lopez C, Sun W, Charpentier K, Shiplkey J, Anderson E, McNulty B. Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. American Society for Clinical Oncology. Orlando, FL, May 2009.
26. Wolf FJ, Beland MD, Grand DJ, Iannitti D, Hass RA, Charpentier KP, Mayo-Smith WW, Machan JT, Dupuy DE. Microwave ablation of hepatic malignancies: Effectiveness and safety in 70 patients. Radiology Society of North America. Chicago, IL Nov 2009.
27. Safran H, Charpentier K, Dubel G, Soares G, Berz D, Shipley J, Faricy-Anderson K, Plette A, Bishop K, Espat J. Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing or intolerant to sorafenib. American Society for Clinical Oncology. Chicago, IL, June 2010.
28. Charpentier KP, Wolf F, Resnick M, Noble L, Winn B, Dupuy D. Irreversible electroporation of the liver and liver hilum in swine. Society for Surgical Oncology. St Lois, MO, March 2010.
29. Jackson KL, Grand DJ, Resnick MB, Charpentier KP. Varying Clinical and radiographic presentation of duodenal gastrointestinal stromal tumors. AHPBA Annual Meeting, Miami, FL, March 2011.

30. Okhah Z, Morrissey P, Harrington D, Cioffi W, Charpentier KP. Performance assessment of surgical residents in a vascular anastomosis laboratory. American College of Surgery, Annual Meeting, San Francisco, CA, October 2011.
31. Safran H, Charpentier K, Kuabisch, A, Dubel G, Soares G, Faricy-Anderson Miner, Eng Y, Ribizzi-Akhtar I, Plette A, Espat J, Schumacher A, Luppe D, Bakalarski P, Wingate P, Victor J, Rosati K, and Isdale D. Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. American Society for Clinical Oncology. Chicago, IL, June 2011.
32. Tempero M, Winter K, Kim GE, Kakar S, Regine WF, Mowat RA, Charpentier KP, Small W; Guha C, Chang DK, Biankin AV. S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): a secondary analysis of RTOG 9704. American Society for Clinical Oncology. Chicago, IL, June 2011.
33. Tempero M, Moughan J, Kim GE, Kakar S, Hyun TS, Regine WF, Mowat RA, Charpentier KP, Small W, Guha C, Chang DK, Biankin AV. S100A4 as a biomarker of resistance to gemcitabine: a secondary analysis of RTOG 9704. American Society for Clinical Oncology. San Francisco, CA, January 2012.
34. Safran H, Charpentier K, Kaubisch A, Dubel G, Perez K, Faricy-Anderson KE, Miner TJ, Victor J, Plette AM, Bakalarski P, Wingate P, Mantripragada KC, Luppe D, Rosati K, Espat J, Isdale D, Eng Y, Martel D, Berz D, Wands J. Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A brown university oncology group phase II study. American Society for Clinical Oncology. Chicago, IL, June 2011.
35. Ratanaprasatporn L, Dupuy D, Resnick M, Lu S, Charpentier KP. Intra-Operative Microwave Ablation of Liver Malignancies with Tumor Permittivity Feedback Control: A Prospective Ablate and Resect Study. New England Surgical Society, Rockport, Maine, September 2012